Phaseline

Companies › Merck & Co. (MSD)

Merck & Co. (MSD): clinical trials, targets and expected readouts

69 active drug programs in 1148 registered trials: 669 Phase 2, 253 Phase 1, 201 Phase 3, 25 Phase 4; Oncology, Other, Infectious disease, Immunology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Sotatercept (MK-7962)
Inhibin beta A chain inhibitor
INHBAPhase 4Pulmonary Arterial Hypertension; Hypertension, Pulmonary; Pulmonary Arterial Hypertension PAH; Eisenmenger Syndrome …Apr 2028
Pembrolizumab
Programmed cell death protein 1 inhibitor
PDCD1Phase 3Melanoma; Non-Small Cell Lung Cancer; Non-small Cell Lung Cancer; Head and Neck Neoplasms …Nov 2026
Enlicitide Decanoate (MK-0616)
PCSK9 inhibitor
PCSK9Phase 3Hyperlipidemia; Hypercholesterolemia; Arteriosclerosis; Lipoprotein(a) …Dec 2026
Belzutifan (MK-6482)
Endothelial PAS domain-containing protein 1 inhibitor
EPAS1Phase 3Carcinoma, Renal Cell; Renal Cell Carcinoma; Von Hippel-Lindau Disease; Neoplasm Malignant …Dec 2026
Sacituzumab Govitecan
Tumor-associated calcium signal transducer 2 binding agent; DNA topoisomerase I inhibitor
TACSTD2, TOP1Phase 3Carcinoma, Non-Small-Cell Lung; Gastroesophageal Cancer; Non-small Cell Lung Cancer (NSCLC); Breast Neoplasms …Jan 2027
9-valent human papillomavirus (9vHPV) vaccine (Types 6, 11, 16, 18, 31, 33, 45,
Aluminum-adjuvanted recombinant protein vaccine containing virus-like particles of recombi
HPV6, HPV11, HPV16, HPV18, HPV31Phase 3Papillomavirus Infections; Genital WartsJan 2027
Nemtabrutinib (MK-1026)
Bruton's tyrosine kinase inhibitor
BTKPhase 3Chronic Lymphocytic Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Hematologic Malignancies; Severe Renal Impairment …Feb 2027
Lenvatinib (MK-7902)
Vascular endothelial growth factor receptor inhibitor
FLT1, FLT4, KDRPhase 3Carcinoma, Renal Cell; Solid Tumors; Neoplasm Malignant; Esophageal Squamous Cell Carcinoma …Feb 2027
Tulisokibart
Humanized monoclonal antibody that binds tumor necrosis factor-like cytokine 1A (TL1A)
TL1APhase 3Crohn's Disease; Ulcerative Colitis; Crohn Disease; Psoriatic Arthritis …Feb 2027
Quavonlimab
CTLA-4 inhibitor
CTLA4Phase 3Carcinoma, Renal CellApr 2027
Intismeran autogene (mRNA-4157, V940)
Autologous tumor-infiltrating lymphocyte (TIL) therapy with mRNA-4157 personalized neoanti
–Phase 3Melanoma; Non-small Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung; Renal Cell Carcinoma …Apr 2027
Olaparib
PARP 1, 2 and 3 inhibitor
PARP1, PARP3, PARP2Phase 3Lung Neoplasms; Small Cell Lung Cancer; Solid Tumors; Advanced Solid Neoplasms …May 2027
EV (Enfortumab Vedotin)
Nectin-4 binding agent; Tubulin inhibitor
NECTIN4, TubulinPhase 3Urinary Bladder Cancer, Muscle-invasive; Bladder Cancer; Metastatic Urothelial CarcinomaMay 2027
Favezelimab
Lymphocyte activation gene 3 protein inhibitor
LAG3Phase 3Solid Tumors; Metastatic Urothelial Carcinoma; Small Cell Lung CarcinomaMay 2027
Suvorexant (MK-4305)
Orexin receptor antagonist
HCRTR2, HCRTR1Phase 3Insomnia; Alcohol Use Disorder (AUD); Suicide Risk; Autism …Jun 2027
Bomedemstat (MK-3543)
Lysine-specific histone demethylase 1 inhibitor
KDM1APhase 3Essential Thrombocythemia; Thrombocythemia, Essential; Polycythemia Vera; Acute Myeloid LeukemiaJul 2027
MK-8527
HIV-1 entry inhibitor
–Phase 3Human Immunodeficiency Virus (HIV); HealthyJul 2027
Islatravir
Reverse transcriptase inhibitor; Human immunodeficiency virus type 1 reverse transcriptase inhibitor
POLG, RTPhase 3HIV-1 Infection; HIV Infection; Human Immunodeficiency Virus Type 1 (HIV-1) InfectionAug 2027
Cirmtuzumab (MK-2140)
Inactive tyrosine-protein kinase transmembrane receptor ROR1 inhibitor
ROR1Phase 3Diffuse Large B-Cell Lymphoma; DLBCL; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large B-Cell, Diffuse (DLBCL) …Sep 2027
Opevesostat (MK-5684)
11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor blocking steroid hormone synt
HSD11B1, ARPhase 3Metastatic Castration-resistant Prostate Cancer (mCRPC); Prostate Cancer Metastatic; Malignant Neoplasm; Prostatic Neoplasms, Castration-Resistant …Nov 2027
V503
9-valent HPV L1 virus-like particle vaccine (types 6, 11, 16, 18, 31, 33, 45, 52, 58)
–Phase 3Papillomavirus InfectionsDec 2027
Calderasib (MK-1084)
KRAS G12C inhibitor
KRASPhase 3Non-small Cell Lung Cancer; Colon Adenocarcinoma; Malignant Neoplasm; Neoplasm Malignant …Jan 2028
Patritumab Deruxtecan
Receptor tyrosine-protein kinase erbB-3 binding agent; DNA topoisomerase I inhibitor
ERBB3, TOP1Phase 3Breast Neoplasms; Non-small Cell Lung Cancer; Gastroesophageal Junction; Gastrointestinal Cancer …May 2028
Ifinatamab Deruxtecan (I-DXd)–Phase 3Prostate Cancer; Carcinoma, Non-Small-Cell Lung; Small Cell Lung Cancer; Malignant Neoplasm …Jun 2028
Doravirine
Human immunodeficiency virus type 1 reverse transcriptase negative allosteric modulator
RT, POLA2, POLGPhase 3HIV-1 Infection; Human Immunodeficiency Virus (HIV) Infection; HIV-1-infection; HIV …Jul 2028
MK-8748–Phase 3Diabetic RetinopathyOct 2028
R-DXD (Raludotatug deruxtecan, MK-5909, DS-6000a)–Phase 3Ovarian Cancer; Gastrointestinal Cancer; Lung Neoplasm; Carcinoma, Non-Small-Cell Lung …Jan 2029
Cetuximab
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 3Colon Adenocarcinoma; Lung Neoplasm MalignantMar 2029
Ensifentrine (MK-5884)
Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor
PDE4A, PDE4D, PDE4B, PDE4C, PDE3APhase 3Pulmonary Disease, Chronic ObstructiveApr 2029
Molnupiravir (MK-4482, LAGEVRIO®)
Nucleoside analog inhibitor of viral RNA-dependent RNA polymerase (RdRp)
RDRPPhase 3Coronavirus Disease (COVID-19); Respiratory Syncytial Virus; COVID-19; DengueJan 2031
V181
Live attenuated dengue virus vaccine
–Phase 3HealthyOct 2031
Ulonivirine (MK-8507)–Phase 2Human Immunodeficiency Virus Type 1 (HIV-1) Infection; HealthyJan 2027
Posaconazole (MK-5592)
Cytochrome P450 51 inhibitor
CYP51A1Phase 2Invasive Fungal Infection; Posaconazole; Breast Cancer; Hematologic MalignancyMar 2027
MK-4830–Phase 2Colorectal Cancer; Esophageal Squamous Cell Carcinoma; Small Cell Lung Carcinoma; Carcinoma, Non-Small-Cell LungJun 2027
MK-7262
Lp(a)-lowering agent
–Phase 2Lipoprotein(a)Oct 2027
MK-8690 (PRA052)–Phase 2Colitis UlcerativeOct 2027
MK-2010
Immune checkpoint inhibitor
–Phase 2Malignant Neoplam; Advanced Solid TumorsSep 2028
ISL/ULO
fixed-dose combination of nucleoside reverse transcriptase translocation inhibitor and non
POLR2APhase 2Human Immunodeficiency Virus Type 1 (HIV-1) InfectionFeb 2029
MK-2214
Anti-tau therapeutic - designed to slow tau accumulation and spread in the brain
–Phase 2Early Alzheimer's DiseaseApr 2029
MK-1045
anti-CD19 bispecific antibody (engaging T cells for B-cell acute lymphoblastic leukemia)
CD19Phase 2Follicular Lymphoma; B-cell Acute Lymphoblastic Leukemia; Chronic Lymphocytic Leukaemia; Systemic Lupus Erythematosus …Jul 2029
Vericiguat
Soluble guanylate cyclase activator
GUCY1B1, GUCY1A2, GUCY1A1Phase 2Heart Failure; Heart Failure With Reduced Ejection Fraction (HFrEF); Endothelial Dysfunction; Post-COVID ME/CFS …Aug 2029
Frespaciguat (MK-5475)
Soluble guanylate cyclase (sGC) stimulator
GUCY1A1, GUCY1B1Phase 2Pulmonary HypertensionOct 2029
Miransertib (MK-7075)
Serine/threonine-protein kinase AKT inhibitor
AKT2, AKT3, AKT1Phase 2PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS); Proteus SyndromeFeb 2030
MK-4646
HIV-1 treatment agent
–Phase 1HealthyNov 2026
V540D
HPV vaccine targeting multiple HPV types including those covered by GARDASIL®9 plus additi
–Phase 1HealthyNov 2026
MK-4082
GLP-1 receptor agonist
GLP1RPhase 1HealthyDec 2026
Infinatamab Deruxtecan (I-DXd, MK-2400)
HER2-targeting antibody-drug conjugate
ERBB2Phase 1Oesophageal Squamous Cell Carcinoma; Small Cell Lung Cancer Extensive Stage; Esophageal Squamous Cell CarcinomaJun 2027
V118E
Pneumococcal polysaccharide conjugate vaccine
–Phase 1HealthyJul 2027
MK-3120
Intravesical immunotherapy
–Phase 1Bladder Cancer; Advanced Solid Tumors; Urothelial CarcinomaJul 2027
Vibostolimab–Phase 1Metastatic Castration-Resistant Prostate Cancer; Carcinoma, Non-Small-Cell LungOct 2027
MK-8644–Phase 1PsoriasisDec 2027
Letermovir (MK-8228)
DNA terminase inhibitor
UL89Phase 1Cytomegalovirus Prophylaxis; Kidney Transplant; CMV; Cytomegalovirus Infections …Apr 2028
V132 Formulation 1
Pneumococcal vaccine
–Phase 1HealthyMay 2028
V540B
Multi-type HPV vaccine with adjuvant
–Phase 1HealthyMay 2028
MK-0472–Phase 1Metastatic Solid TumorsJun 2028
V350A
EBV vaccine
–Phase 1HealthyJul 2028
V350B
EBV vaccine
–Phase 1HealthyJul 2028
V175
RSV multivalent vaccine
–Phase 1Lower Respiratory Tract InfectionAug 2028
V175A
RSV multivalent vaccine
–Phase 1Lower Respiratory Tract InfectionAug 2028
MK-1045
Immunotherapy for B-cell lymphoma
–Phase 1Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma; Acute Lymphoblastic LeukemiaSep 2028
V118C
pneumococcal polysaccharide conjugate vaccine
–Phase 1Pneumococcal InfectionOct 2028
Gocatamig (MK-6070)
T-cell engager
–Phase 1Small Cell Lung Cancer; Small Cell Lung Cancer Extensive StageFeb 2029
MK-8294–Phase 1Metastatic NeoplasmJul 2029
MK-4884–Phase 1Malignant NeoplasmOct 2029
MK-4716–Phase 1Malignant NeoplasmDec 2030
Boserolimab
TIM-3 inhibitor
HAVCR2Phase 1Carcinoma, Non-Small-Cell LungFeb 2032
MK-0482
Toll-like receptor agonist
–Phase 1Carcinoma, Non-Small-Cell LungFeb 2032
MK-1403–Phase 1Healthy–
MK-1484–Phase 1Advanced or Metastatic Solid Tumors–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT02362594PembrolizumabPhase 3MelanomaOncologyJan 2018
NCT02998268PembrolizumabPhase 2Esophageal AdenocarcinomaOncologyFeb 2021
NCT03591276PembrolizumabPhase 1Metastatic Breast CancerOncologyApr 2021
NCT02641093PembrolizumabPhase 2Head and Neck CancerOncologyApr 2021
NCT03468218PembrolizumabPhase 2Metastatic Head and Neck CarcinomaOncologyMay 2022
NCT02743819PembrolizumabPhase 2MelanomaOncologyJun 2022
NCT02852655PembrolizumabPhase 1Brain CancerOncologyJun 2022
NCT03698019PembrolizumabPhase 2Acral Lentiginous MelanomaOncologySep 2022
NCT03753243PembrolizumabPhase 2Prostate CancerOncologySep 2022
NCT02752685PembrolizumabPhase 2Breast CancerOncologyDec 2022
NCT04956692PembrolizumabPhase 3Non-Small Cell Lung CancerOncologyApr 2023
NCT04956692PembrolizumabPhase 3Non-Small Cell Lung CancerOncologyApr 2023
NCT04014530PembrolizumabPhase 1Colorectal CancerOncologyJun 2023
NCT02965716PembrolizumabPhase 2Advanced MelanomaOncologyJun 2023
NCT03425643PembrolizumabPhase 3Non-small Cell Lung CancerOncologyJul 2023
NCT04857164PembrolizumabPhase 2Head and Neck Squamous Cell CarcinomaOncologyAug 2023
NCT03385226PembrolizumabPhase 2Cutaneous T Cell LymphomaOncologySep 2023
NCT03732950PembrolizumabPhase 2Recurrent Fallopian Tube CarcinomaOncologyDec 2023
NCT03813836PembrolizumabPhase 2Metastatic Head and Neck Squamous Cell CarcinomaOncologyJan 2024
NCT04195750Belzutifan (MK-6482)Phase 3Carcinoma, Renal CellOncologyApr 2024
NCT03488667PembrolizumabPhase 2Gastro Esophageal Junction CancerOncologyApr 2024
NCT05824468Lenvatinib (MK-7902)Phase 2Cervical CancerOncologyJul 2024
NCT03813394PembrolizumabPhase 1Locally Recurrent CancerOncologyJul 2024
NCT04009967PembrolizumabPhase 2Prostate CancerOncologySep 2024
NCT03971045PembrolizumabPhase 2Breast CancerOncologyDec 2024
NCT03971045PembrolizumabPhase 2Breast CancerOncologyDec 2024
NCT06482086Lenvatinib (MK-7902)Phase 2Locally Advanced Thyroid Gland CarcinomaOncologyDec 2024
NCT04287829PembrolizumabPhase 2Mesotheliomas PleuralOncologyDec 2024
NCT04287829Lenvatinib (MK-7902)Phase 2Mesotheliomas PleuralOncologyDec 2024
NCT04777084Lenvatinib (MK-7902)Phase 2Non-Small Cell Lung CancerOncologyDec 2024
NCT05033756PembrolizumabPhase 2Malignant Neoplasm of BreastOncologyJan 2025
NCT03474497PembrolizumabPhase 1Non Small Cell Lung CancerOncologyApr 2025
NCT04895722PembrolizumabPhase 2Colorectal CancerOncologyMay 2025
NCT04895722MK-4830Phase 2Colorectal CancerOncologyMay 2025
NCT05252429PembrolizumabPhase 2Effect of DrugOncologyMay 2025
NCT04340258PembrolizumabPhase 1HNSCCOncologyJun 2025
NCT05745350PembrolizumabPhase 2Small Cell Lung Cancer Extensive StageOncologyJun 2025
NCT05113186Lenvatinib (MK-7902)Phase 2Hepatocellular CarcinomaOncologyJun 2025
NCT03240211PembrolizumabPhase 1PTCLOncologyJul 2025
NCT05824481Lenvatinib (MK-7902)Phase 2Endometrial CancerOncologyJul 2025
NCT05010681Lenvatinib (MK-7902)Phase 2Intrahepatic CholangiocarcinomaOncologyAug 2025
NCT06880029PembrolizumabPhase 1Triple Negative Breast Cancer (TNBC)OncologySep 2025
NCT04030455PembrolizumabPhase 2Laryngeal Squamous Cell CarcinomaOncologySep 2025
NCT04869137PembrolizumabPhase 2Merkel Cell CarcinomaOncologySep 2025
NCT04869137Lenvatinib (MK-7902)Phase 2Merkel Cell CarcinomaOncologySep 2025
NCT04373642PembrolizumabPhase 2Head and Neck CancerOncologyOct 2025
NCT05595447PembrolizumabPhase 2Hodgkin LymphomaOncologyOct 2025
NCT05098847Lenvatinib (MK-7902)Phase 2Liver MetastasisOncologyOct 2025
NCT04513626DoravirinePhase 2HIV InfectionsInfectious diseaseOct 2025
NCT02778685PembrolizumabPhase 2Metastatic Breast CarcinomaOncologyOct 2025
NCT05508737PembrolizumabPhase 1Gastric and Gastroesophageal Junction AdenocarcinomaOncologyNov 2025
NCT04825990PembrolizumabPhase 2Nasopharyngeal CarcinomaOncologyNov 2025
NCT03512405PembrolizumabPhase 1CD19 PositiveOncologyNov 2025
NCT03029403PembrolizumabPhase 2Advanced CancerOncologyDec 2025
NCT04547504PembrolizumabPhase 3Non-small-cell Lung CancerOncologyDec 2025
NCT04547504PembrolizumabPhase 3Non-small-cell Lung CancerOncologyDec 2025
NCT06032845Lenvatinib (MK-7902)Phase 2Solid Tumor, AdultOncologyDec 2025
NCT03717623Posaconazole (MK-5592)Phase 4PosaconazoleInfectious diseaseDec 2025
NCT06230471PembrolizumabPhase 2Biliary Tract Neoplasms ImmunotherapyOncologyDec 2025
NCT04592211PembrolizumabPhase 1Gastric Cancer Stage IVOncologyDec 2025

The 60 nearest readouts of 1148 trials; the rest in the app.

Specialist investors

Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

TOP1 (2) GUCY1B1 (2) GUCY1A1 (2) POLG (2) RT (2) PDCD1 (1) PARP1 (1) PARP3 (1) PARP2 (1) TACSTD2 (1) AKT2 (1) AKT3 (1)

Companies with the same targets

AstraZeneca Akeso Gilead Sciences GSK Daiichi Sankyo Sichuan Baili Pharmaceutical Innovent Biologics (Suzhou) Shanghai Henlius Biotech Shenyang Sunshine Pharmaceutical Pulmovant

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.